ADHD prescriptions for Ontario adults doubled since pandemic, study shows

ADHD prescriptions for Ontario adults doubled since the pandemic (≈100% increase). Researchers attribute the rise to increased adult diagnoses and changing access patterns and flag concerns about escalating prescribing rates, potential overdiagnosis and long-term safety. This is primarily a public-health development with limited direct market implications.

Analysis

The surge in adult ADHD prescribing is less a standalone pharmaceutical bull case and more a structural demand shock driven by two durable enablers: scaled telemedicine distribution and a one-time diagnostic gap from the pandemic cohort. For large generic manufacturers and pharmacy chains, this trend is likely to produce a low-single-digit percent revenue tailwind over 12–24 months (translating into ~50–150bps of incremental top-line for a diversified generic/retail player), but materially less upside for branded specialty pharma because payers can blunt unit-price gains.

Second-order supply effects matter: API/CMO capacity for stimulants and the contract-manufacturing bottlenecks will surface within 3–9 months if growth continues, creating episodic price spikes and order prioritization that benefit flexible CMO partners and integrated distributors. Conversely, PBMs and provincial insurers retain strong levers — expect prior-authorization rollouts or refill-interval tightening within 6–18 months that will compress ARPU per patient even as volumes rise, shifting value from manufacturers to distributors and scale-efficient telehealth platforms.

The main tail risks are regulatory and payer-led: clinic-level prescribing audits, tightened remote-prescribing rules, or formulary changes can reverse growth within quarters. The consensus trade — unhedged exposure to telehealth/psychiatry names — underestimates policy execution risk; a more defensible approach is to capture volume upside while hedging for 6–18 month regulatory intervention scenarios and potential saturation once the untreated adult pool is addressed.

Key Decisions for Investors

• Long TDOC (Teladoc) 9–12 month call spread (buy a near-term ITM call / sell a higher strike) to capture recurring remote-prescription revenue growth; hedge by buying a 9-month out-of-the-money put (1:0.4) to protect vs regulatory clampdowns. R/R: limited debit on spread with 2–3x upside vs put-protected downside over 12 months.
• Long TEVA (Teva) 6–12 month call options or a bullish call spread to play steady generic stimulant volumes. Rationale: volume growth with limited pricing power — use a spread to cap premium; target payoff if volume-driven revenue adds 50–150bps to top-line. Risk: aggressive PBM formularies could keep upside muted.
• Pair trade: long CVS (CVS) or WBA (Walgreens) 6–12 month equity exposure vs short HIMS (HIMS) or small-cap tele-mental-health names (equal notional). Mechanism: retail pharmacies capture incremental dispensing revenue and sticky refill flows, while pure-play, prescription-first telehealth platforms are most exposed to utilization-management and remote-prescribing restrictions. Expect alpha if payers tighten remote scripts within 6–12 months; set stop-loss at 10–15%.
• Event hedge: buy 6–9 month out-of-the-money puts on the telehealth cohort (TDOC/HIMS) sized to cover 30–50% of bullish exposure. Use these as insurance against a regulatory/policy shock (announcements or provincial audits) that could unwind multiples rapidly; cost is insurance premium but protects concentrated upside positions.